Guido Alves

List of Publications by Citations

107 papers	5,947 citations	40 h-index	76 g-index
127 ext. papers	7,043 ext. citations	5.8 avg, IF	5.69 L-index

#	Paper	IF	Citations
107	Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. *Neurology*, **2009**, 72, 1121-6	6.5	488
106	Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. *Lancet Neurology, The*, **2009**, 8, 613-8	24.1	358
105	Changes in motor subtype and risk for incident dementia in Parkinson's disease. *Movement Disorders*, **2006**, 21, 1123-30	7	320
104	Epidemiology of Parkinson's disease. *Journal of Neurology*, **2008**, 255 Suppl 5, 18-32	5.5	257
103	A 12-year population-based study of psychosis in Parkinson disease. *Archives of Neurology*, **2010**, 67, 996-1001		246
102	Epidemiology of psychosis in Parkinson's disease. *Journal of the Neurological Sciences*, **2010**, 289, 12-7	3.2	231
101	Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. *JAMA Neurology*, **2013**, 70, 580-6	17.2	222
100	What predicts mortality in Parkinson disease?: a prospective population-based long-term study. *Neurology*, **2010**, 75, 1270-6	6.5	201
99	Progression of motor impairment and disability in Parkinson disease: a population-based study. *Neurology*, **2005**, 65, 1436-41	6.5	196
98	The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2009**, 80, 928-30	5.5	189
97	Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2009**, 80, 851-7	5.5	165
96	Is fatigue an independent and persistent symptom in patients with Parkinson disease?. *Neurology*, **2004**, 63, 1908-11	6.5	156
95	Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. *Movement Disorders*, **2010**, 25, 805-22	7	152
94	CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 1080-6	5.5	151
93	Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?. *Neurology*, **2006**, 67, 853-8	6.5	151
92	Predictors and course of health-related quality of life in Parkinson's disease. *Movement Disorders*, **2008**, 23, 1420-7	7	128
91	CSF A□2 predicts early-onset dementia in Parkinson disease. *Neurology*, **2014**, 82, 1784-90	6.5	108

90	Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. *Parkinsonism and Related Disorders*, **2009**, 15, 295-9	3.6	108
89	Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study. *Neurology*, **2017**, 88, 767-774	6.5	106
88	Cellular Proteostasis in Neurodegeneration. *Molecular Neurobiology*, **2019**, 56, 3676-3689	6.2	79
87	The Arabidopsis DJ-1a protein confers stress protection through cytosolic SOD activation. *Journal of Cell Science*, **2010**, 123, 1644-51	5.3	77
86	Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2009**, 80, 1279-82	5.5	77
85	Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. *Journal of Neurology*, **2010**, 257, 217-23	5.5	73
84	Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. *Neuropsychology*, **2011**, 25, 114-24	3.8	71
83	microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases. *Cellular and Molecular Life Sciences*, **2016**, 73, 811-27	10.3	69
82	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. *Movement Disorders*, **2019**, 34, 1839-1850	7	69
81	A 12-year population-based study of freezing of gait in Parkinson's disease. *Parkinsonism and Related Disorders*, **2015**, 21, 254-8	3.6	68
80	Cigarette smoking in Parkinson's disease: influence on disease progression. *Movement Disorders*, **2004**, 19, 1087-1092	7	62
79	Risk and course of motor complications in a population-based incident Parkinson's disease cohort. *Parkinsonism and Related Disorders*, **2016**, 22, 48-53	3.6	61
78	Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. *Acta Neuropathologica*, **2018**, 135, 409-425	14.3	59
77	Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts. *Neurology: Genetics*, **2019**, 5, e348	3.8	57
76	Parkinson's disease and age: The obvious but largely unexplored link. *Experimental Gerontology*, **2015**, 68, 33-8	4.5	55
75	White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. *NeuroImage*, **2009**, 47, 2083-9	7.9	54
74	Gray matter correlations of cognition in incident Parkinson's disease. *Movement Disorders*, **2010**, 25, 629-33	7	52
73	Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment. *Neurobiology of Aging*, **2012**, 33, 2113-24	5.6	51

72	Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 537-43	5.5	48
71	Psychometric properties of the Starkstein Apathy Scale in patients with early untreated Parkinson disease. *American Journal of Geriatric Psychiatry*, **2012**, 20, 142-8	6.5	47
70	Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. *Movement Disorders*, **2011**, 26, 297-301	7	43
69	Brain atrophy and white matter hyperintensities in early Parkinson's disease(a). *Movement Disorders*, **2009**, 24, 2233-41	7	43
68	APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. *Journal of Geriatric Psychiatry and Neurology*, **2009**, 22, 166-70	3.8	42
67	Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2008**, 25, 559-63	2.6	40
66	CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 160-4	5.5	38
65	Impulsive and Compulsive Behaviors in Parkinson's Disease: The Norwegian ParkWest Study. *Journal of Parkinson's Disease*, **2017**, 7, 183-191	5.3	35
64	Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study. *Neurology*, **2016**, 87, 1599-1606	6.5	32
63	Rare genetic variation in mitochondrial pathways influences the risk for Parkinson's disease. *Movement Disorders*, **2018**, 33, 1591-1600	7	30
62	Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study. *Neurology*, **2019**, 93, e1526-e1534	6.5	29
61	Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease. *Neurobiology of Aging*, **2018**, 63, 120-127	5.6	27
60	LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation. *Journal of Neuroscience Research*, **2016**, 94, 717-35	4.4	27
59	Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease. *Parkinsonism and Related Disorders*, **2018**, 49, 4-8	3.6	23
58	Cerebrospinal fluid Aβ1 levels correlate with structural brain changes in Parkinson's disease. *Movement Disorders*, **2013**, 28, 302-10	7	23
57	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. *Frontiers in Aging Neuroscience*, **2016**, 8, 147	5.3	23
56	Familial Parkinson's disease: a community-based study. *European Journal of Neurology*, **2003**, 10, 159-63	6	22
55	Clinical milestones in Parkinson's disease: A 7-year population-based incident cohort study. *Parkinsonism and Related Disorders*, **2017**, 42, 28-33	3.6	22

54	Combinatory microRNA serum signatures as classifiers of Parkinson's disease. *Parkinsonism and Related Disorders*, **2019**, 64, 202-210	3.6	19
53	A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells. *PLoS ONE*, **2015**, 10, e0143969	3.7	19
52	Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson's Disease. *Journal of Parkinson's Disease*, **2020**, 10, 1087-1098	5.3	19
51	Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson's Disease. *Frontiers in Neurology*, **2018**, 9, 109	4.1	18
50	Disorders of motivation, sexual conduct, and sleep in Parkinson's disease. *Advances in Neurology*, **2005**, 96, 56-64		18
49	Long-term risk of falls in an incident Parkinson's disease cohort: the Norwegian ParkWest study. *Journal of Neurology*, **2017**, 264, 364-372	5.5	17
48	New insight into neurodegeneration: the role of proteomics. *Molecular Neurobiology*, **2014**, 49, 1181-99	6.2	17
47	Hyposmia in a simple smell test is associated with accelerated cognitive decline in early Parkinson's disease. *Acta Neurologica Scandinavica*, **2018**, 138, 508-514	3.8	16
46	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD. *Neuroepidemiology*, **2015**, 45, 282-97	5.4	16
45	Common gene expression signatures in Parkinson's disease are driven by changes in cell composition. *Acta Neuropathologica Communications*, **2020**, 8, 55	7.3	16
44	Differences in the Presentation and Progression of Parkinson's Disease by Sex. *Movement Disorders* , **2021**, 36, 106-117	7	16
43	Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. *Alzheimer's and Dementia*, **2018**, 14, 1293-1301	1.2	16
42	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. *Nature Genetics*, **2021**, 53, 787-793	36.3	15
41	Inflammation and fatigue in early, untreated Parkinson's Disease. *Acta Neurologica Scandinavica*, **2018**, 138, 394-399	3.8	13
40	Reliability of Three Disability Scales for Detection of Independence Loss in Parkinson's Disease. *Parkinson's Disease*, **2016**, 2016, 1941034	2.6	12
39	Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia. *Journal of the American Geriatrics Society*, **2020**, 68, 2257-2263	5.6	11
38	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. *Frontiers in Aging Neuroscience*, **2016**, 8, 121	5.3	10
37	Differential transcript usage in the Parkinson's disease brain. *PLoS Genetics*, **2020**, 16, e1009182	6	9

36	Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration. *Molecular Neurobiology*, **2017**, 54, 7639-7655	6.2	8
35	Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease. *Neuroscience Letters*, **2018**, 674, 123-126	3.3	7
34	Excessive Daytime Sleepiness and REM Sleep Behavior Disorders in Parkinson's Disease: A Narrative Review on Early Intervention With Implications to Neuroprotection. *Frontiers in Neurology*, **2018**, 9, 961	4.1	7
33	Association of a BACE1 Gene Polymorphism with Parkinson's Disease in a Norwegian Population. *Parkinson's Disease*, **2015**, 2015, 973298	2.6	6
32	Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. *Neurology*, **2021**, 96, e1036-e1044	6.5	6
31	Early constipation predicts faster dementia onset in Parkinson's disease. *Npj Parkinson's Disease*, **2021**, 7, 45	9.7	6
30	Neurofilament light is a biomarker of brain involvement in lupus and primary Sjögren's syndrome. *Journal of Neurology*, **2021**, 268, 1385-1394	5.5	6
29	Validation of a new assay for α-synuclein detection in cerebrospinal fluid. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 254-260	5.9	5
28	Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson's disease brain. *Molecular Neurodegeneration*, **2021**, 16, 31	19	5
27	The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. *European Journal of Neurology*, **2020**, 27, 43-50	6	5
26	Progression of fatigue in Parkinson's disease - a 9-year follow-up. *European Journal of Neurology*, **2021**, 28, 108-116	6	5
25	Impulsive and compulsive behaviors in Parkinson's disease: Impact on quality of and satisfaction with life, and caregiver burden. *Parkinsonism and Related Disorders*, **2020**, 78, 27-30	3.6	4
24	Genetic risk scores and hallucinations in patients with Parkinson disease. *Neurology: Genetics*, **2020**, 6, e492	3.8	4
23	Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. *Parkinsonism and Related Disorders*, **2020**, 76, 49-53	3.6	3
22	No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease. *Brain*, **2018**, 141, e16	11.2	3
21	Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci. *PLoS ONE*, **2020**, 15, e0239824	3.7	3
20	Validation and assessment of preanalytical factors of a fluorometric in vitro assay for glucocerebrosidase activity in human cerebrospinal fluid. *Scientific Reports*, **2020**, 10, 22098	4.9	3
19	Evolution of impulsive-compulsive behaviors and cognition in Parkinson's disease. *Journal of Neurology*, **2020**, 267, 259-266	5.5	3

18	A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson's disease. *Npj Parkinson's Disease*, **2021**, 7, 54	9.7	3
17	CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis.. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 20552173211060337	3	2
16	GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.. *Movement Disorders*, **2022**,	7	2
15	Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. *Journal of Neurology*, **2021**, 1	5.5	2
14	Common gene expression signatures in Parkinson's disease are driven by changes in cell composition		2
13	Genome-wide dysregulation of histone acetylation in the Parkinson's disease brain		2
12	Association of Parkinson's Disease Risk Polymorphisms With Disease Progression in Newly Diagnosed Patients. *Frontiers in Neurology*, **2020**, 11, 620585	4.1	1
11	Ultra-deep whole genome bisulfite sequencing reveals a single methylation hotspot in human brain mitochondrial DNA		1
10	The impact of common genetic variants in cognitive decline in the first seven years of Parkinson's disease: A longitudinal observational study. *Neuroscience Letters*, **2021**, 764, 136243	3.3	1
9	Early Forms of α-Synuclein Pathology Are Associated with Neuronal Complex I Deficiency in the Substantia Nigra of Individuals with Parkinson's Disease. *Biomolecules*, **2022**, 12, 747	5.9	1
8	Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson's Disease Cohorts. *Journal of Parkinson's Disease*, **2021**, 11, 1569-1578	5.3	0
7	Ultra-deep whole genome bisulfite sequencing reveals a single methylation hotspot in human brain mitochondrial DNA.. *Epigenetics*, **2022**, 1-16	5.7	0
6	Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.. *Movement Disorders Clinical Practice*, **2022**, 9, 479-483	2.2	0
5	Parkinson's disease clinical milestones and mortality.. *Npj Parkinson's Disease*, **2022**, 8, 58	9.7	0
4	Neuropsychiatric symptoms correlated with functional trajectories among people living with Alzheimer's disease dementia and Lewy body dementia. *Alzheimer's and Dementia*, **2020**, 16, e041881	1.2	
3	Is psychosis associated with impulse control disorders in Parkinson's disease?. *Parkinsonism and Related Disorders*, **2018**, 53, 110-111	3.6	
2	A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease. *Movement Disorders*, **2019**, 34, 298-299	7	
1	Letter to the editor in response to the letter from the EPIPARK Study Group regarding the publication 'Progression of fatigue in Parkinson's disease - a 9-year follow-up' (Eur J Neurol 2021. doi:10.1111/ene.14520). *European Journal of Neurology*, **2021**, 28, e33-e34	6	